Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer

• Status: Unknown status
• Trial end date: 1969-12-31

Summary

To study the pharmacokinetic profile of the therapeutic schedule in order to demonstrate absence of negative interactions among the 3 drugs administered

• Phase: Phase 2

Details

• Lead Sponsor: Zeneus Pharma
• Treatments: Docetaxel; Doxorubicin; Liposomal doxorubicin; Trastuzumab